In the dynamic and rapidly advancing field of oncology diagnostics, Immunovia has launched a groundbreaking pancreatic cancer diagnostic test, the IMMray PanCan-d, marking a significant leap in early cancer detection.

This innovation aims to transform the landscape of pancreatic cancer diagnostics by enhancing the accuracy and applicability of early detection tests.

Typically diagnosed through a combination of symptom assessment and traditional biomarkers, pancreatic cancer detection is poised for transformation with Immunovia’s latest diagnostic technology.

The new IMMray PanCan-d test significantly improves upon previous models by demonstrating a specificity of 98% and a sensitivity of 75% for detecting early-stage 1 and 2 pancreatic cancers.

It outperforms the commonly used CA19-9 biomarker, which some patients cannot produce, thereby widening the test’s applicability to a broader patient demographic.

This test leverages Immunovia’s refined antibody microarray analysis technology, enhancing both the precision and reach of pancreatic cancer diagnostics.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to GlobalData, a leading data and analytics company, the market for oncology diagnostics is projected to grow from $1.5bn in 2023 to $2.3bn by 2030.

This growth is driven by the demand for early disease diagnosis and personalised medicine, propelling advancements in the sector.

The IMMray PanCan-d test contributes significantly to this sector, promising improved patient outcomes by enabling the detection of pancreatic cancer at more treatable stages.

The potential of this advanced diagnostic test to improve diagnosis efficiency and patient care is a testament to the rapid evolution of oncology diagnostics.

By integrating sophisticated diagnostic technologies with practical clinical applications, Immunovia is setting new standards in the field.

This development represents a pivotal moment in oncology diagnostics, contributing to the sector’s increasingly crucial role in preventive healthcare and early disease detection.

As the global population ages and the prevalence of pancreatic cancer rises, the effectiveness, accuracy, and accessibility of early diagnostics are paramount.

Immunovia’s launch of the IMMray PanCan-d test not only showcases the potential of advanced diagnostic methods but also sets the stage for a new era of capabilities that promise to significantly impact patient care and outcomes.